E6888

Enalapril maleate salt

Name: Enalapril maleate salt
Brand: SIGMA

≥98.0% (HPLC), ACE inhibitor, powder

동의어(들):

(S)-N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-Ala-Pro maleate salt

조직 및 계약 가격을 보려면 로그인를 클릭합니다.

크기 선택

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):

C₂₀H₂₈N₂O₅ · C₄H₄O₄

CAS 번호:

76095-16-4

Molecular Weight:

492.52

UNSPSC Code:

12352200

PubChem Substance ID:

24894639

NACRES:

NA.77

EC Number:

278-375-7

주요 문서

모든 문서 보기

기술 서비스

도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.

도움 문의

기술 서비스

도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.

도움 문의

제품 이름

Enalapril maleate salt, powder, ≥98.0% (HPLC)

InChI

1S/C21H30N2O5.C4H4O5/c1-3-28-19(24)14-17(12-11-16-8-5-4-6-9-16)22-15(2)20(25)23-13-7-10-18(23)21(26)27;5-3(6)1-2-4(7)9-8/h4-6,8-9,15,17-18,22H,3,7,10-14H2,1-2H3,(H,26,27);1-2,8H,(H,5,6)/b;2-1-/t15-,17-,18-;/m0./s1

InChI key

UQKQUZOIQFOJOI-KJHLASMFSA-N

SMILES string

C[C@@H](C(N1[C@H](C(O)=O)CCC1)=O)N[C@H](CC(OCC)=O)CCC2=CC=CC=C2.O=C(OO)/C=C\C(O)=O

form

powder

color

white to off-white

solubility

methanol: ≥50 mg/mL, clear, colorless to yellow

originator

Merck & Co., Inc., Kenilworth, NJ, U.S.

Quality Level

100

assay

≥98.0% (HPLC)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

General description

Enalapril is an angiotensin-converting enzyme inhibitor. It is used to treat heart failure and high blood pressure.

Application

Enalapril maleate salt has been used:

to reduce albumin excretion rate (AER) and glomerular lesions
to examine the effects of enalapril pre-treatment on myocardial injury
to investigate its efficacious doses and schedules for mitigation of radiation lung injury

Biochem/physiol Actions

A long-acting angiotensin-converting enzyme inhibitor.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

GHS08

signalword

Warning

hcodes

H361fd

pcodes

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 2

저장 등급

11 - Combustible Solids

wgk

WGK 2

ppe

Eyeshields, Gloves, type N95 (US)

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Effects of soluble guanylate cyclase stimulator on renal function in ZSF-1 model of diabetic nephropathy.

Lufei Hu et al.

PloS one, 17(1), e0261000-e0261000 (2022-01-28)

Diabetic nephropathy is associated with endothelial dysfunction and oxidative stress, in which the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway is impaired. We hypothesize that sGC stimulator Compound 1 can enhance NO signaling, reduce proteinuria in a diabetic

Association of Proteinuria with Urinary Concentration Defect in Puromycin Aminonucleoside Nephrosis.

Chor Ho Jo et al.

Electrolyte & blood pressure : E & BP, 18(2), 31-39 (2021-01-08)

Puromycin aminonucleoside (PA) can induce nephrotic syndrome in rats, and proteinuria is an important mediator of tubulointerstitial injury in glomerulopathy. We assumed that glomerular proteinuria may affect tubular function, such as urinary concentration, and investigated whether a urinary concentration defect

Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice

Klein J, et al.

Kidney International, 90(5), 1045-1055 (2016)

Enalapril

Todd PA and Heel RC

Drugs, 31(3), 198-248 (1986)

Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells.

Guang Liu et al.

American journal of physiology. Renal physiology, 319(4), F697-F711 (2020-09-01)

Praliciguat, a clinical-stage soluble guanylate cyclase (sGC) stimulator, increases cGMP via the nitric oxide-sGC pathway. Praliciguat has been shown to be renoprotective in rodent models of hypertensive nephropathy and renal fibrosis. In the present study, praliciguat alone and in combination

모든 관련된 서류 보기

문서

Discover Bioactive Small Molecules for ADME/Tox

Enalapril maleate salt

≥98.0% (HPLC), ACE inhibitor, powder

크기 선택

제품정보 (DICE 배송 시 비용 별도)

주요 문서

속성

제품 이름

InChI

InChI key

SMILES string

form

color

solubility

originator

Quality Level

assay

관련 카테고리

설명

General description

Application

Biochem/physiol Actions

Features and Benefits

안전성 정보

pictograms

signalword

hcodes

pcodes

Hazard Classifications

저장 등급

wgk

ppe

문서

시험 성적서(COA)

이 제품을 이미 가지고 계십니까?

관련 참고 논문

관련 참고 프로토콜

문서

관련 콘텐츠

기술 서비스